🚀 VC round data is live in beta, check it out!
Frontage Laboratories Valuation Multiples
Discover revenue and EBITDA valuation multiples for Frontage Laboratories and similar public comparables like Dishman Carbogen Amics, Australian Clinical Labs, Eurobio Scientific, Lifecore Biomedical and more.
Frontage Laboratories Overview
About Frontage Laboratories
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
Founded
2018
HQ
Employees
1.6K
Website
Financials (LTM)
EV
$395M
Frontage Laboratories Financials
Frontage Laboratories reported last 12-month revenue of $260M and EBITDA of $39M.
In the same LTM period, Frontage Laboratories generated $39M in EBITDA and $7M in net income.
Revenue (LTM)
Frontage Laboratories P&L
In the most recent fiscal year, Frontage Laboratories reported revenue of $255M and EBITDA of $50M.
Frontage Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $260M | XXX | $255M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $70M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $39M | XXX | $50M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $7M | XXX | $791K | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | — | — | $52M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Frontage Laboratories Stock Performance
Frontage Laboratories has current market cap of $292M, and enterprise value of $395M.
Market Cap Evolution
Frontage Laboratories' stock price is $0.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $395M | $292M | -0.1% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFrontage Laboratories Valuation Multiples
Frontage Laboratories trades at 1.5x EV/Revenue multiple, and 10.3x EV/EBITDA.
EV / Revenue (LTM)
Frontage Laboratories Financial Valuation Multiples
As of March 19, 2026, Frontage Laboratories has market cap of $292M and EV of $395M.
Equity research analysts estimate Frontage Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Frontage Laboratories has a P/E ratio of 39.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $292M | XXX | $292M | XXX | XXX | XXX |
| EV (current) | $395M | XXX | $395M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 10.3x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBIT | 21.0x | XXX | 42.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.7x | XXX | XXX | XXX |
| P/E | 39.3x | XXX | 369.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 26.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Frontage Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Frontage Laboratories Margins & Growth Rates
Frontage Laboratories' revenue in the last 12 month grew by 8%.
Frontage Laboratories' revenue per employee in the last FY averaged $0.2M.
Frontage Laboratories' rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Frontage Laboratories' rule of X is 34% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Frontage Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | (24%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 19% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Frontage Laboratories Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Eurobio Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| Lifecore Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Binex | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Frontage Laboratories M&A Activity
Frontage Laboratories acquired XXX companies to date.
Last acquisition by Frontage Laboratories was on XXXXXXXX, XXXXX. Frontage Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Frontage Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialFrontage Laboratories Investment Activity
Frontage Laboratories invested in XXX companies to date.
Frontage Laboratories made its latest investment on XXXXXXXX, XXXXX. Frontage Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Frontage Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Frontage Laboratories
| When was Frontage Laboratories founded? | Frontage Laboratories was founded in 2018. |
| Where is Frontage Laboratories headquartered? | Frontage Laboratories is headquartered in United States. |
| How many employees does Frontage Laboratories have? | As of today, Frontage Laboratories has over 1K employees. |
| Is Frontage Laboratories publicly listed? | Yes, Frontage Laboratories is a public company listed on HKEX. |
| What is the stock symbol of Frontage Laboratories? | Frontage Laboratories trades under 01521 ticker. |
| When did Frontage Laboratories go public? | Frontage Laboratories went public in 2019. |
| Who are competitors of Frontage Laboratories? | Frontage Laboratories main competitors are Dishman Carbogen Amics, Australian Clinical Labs, Eurobio Scientific, Lifecore Biomedical. |
| What is the current market cap of Frontage Laboratories? | Frontage Laboratories' current market cap is $292M. |
| What is the current revenue of Frontage Laboratories? | Frontage Laboratories' last 12 months revenue is $260M. |
| What is the current revenue growth of Frontage Laboratories? | Frontage Laboratories revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Frontage Laboratories? | Current revenue multiple of Frontage Laboratories is 1.5x. |
| Is Frontage Laboratories profitable? | Yes, Frontage Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Frontage Laboratories? | Frontage Laboratories' last 12 months EBITDA is $39M. |
| What is Frontage Laboratories' EBITDA margin? | Frontage Laboratories' last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Frontage Laboratories? | Current EBITDA multiple of Frontage Laboratories is 10.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.